Cytosorbents (CTSO) CEO Phillip Chan Buys $100K of Stock

Phillip Chan, Chief Executive Officer of Cytosorbents Corporation, recently bought 251,136 shares of the company. The purchase, made on June 12, 2026, was at an average price of $0.4 per share, totaling $100,454.4. This move reflects Chan's continued commitment to the company.

Other Institutional Activity in Cytosorbents

Several institutional investors have also been active in Cytosorbents. Vanguard Capital Management LLC significantly increased its holdings by 1,879,989 shares, ending with a total of 1,879,989 shares valued at approximately $1.06 million. Conversely, Skylands Capital, LLC reduced its position by 147,017 shares, leaving it with 1,707,498 shares worth about $966,956. Neuberger Berman Group LLC added 57,367 shares to its portfolio, now holding 1,683,007 shares valued at $950,776. Meanwhile, Avenir Corp trimmed its holdings by 14,323 shares, holding 5,215,776 shares valued at $2.95 million.

Cytosorbents Corporation Stock Down 92.5%

Cytosorbents Corporation, trading under the ticker CTSO on the NasdaqCM, has a market cap of approximately $27.13 million. The stock recently traded at around $0.4, with a 52-week low of $0.37 and a high of $1.39. The company's 50-day moving average is $0.55, and the 200-day average is $0.71. Cytosorbents has a high debt-to-equity ratio of 1334.366, indicating significant leverage.

Recent Earnings

In its most recent financial report, Cytosorbents posted revenue of $37.2 million, marking a modest growth of 1.6%. However, the company reported a negative net margin of 31.85% and a return on equity of -141.58%. The next earnings announcement is expected on August 6, 2026.

Insider Buying and Selling at Cytosorbents Corporation

Phillip Chan has been active in trading shares of Cytosorbents. On June 12, 2026, he purchased 251,136 shares at $0.4 each. Additionally, on June 15, 2026, Chan bought another 10,333 shares at $0.43 per share. These purchases were not part of any pre-planned trading program.

Analysts Set New Price Targets

Analysts have been monitoring Cytosorbents closely. On January 12, 2026, D. Boral Capital maintained its "buy" rating with a price target of $10. Meanwhile, HC Wainwright & Co. has a "hold" rating with a target of $0.75. Overall, the consensus target price is $2.88 based on two analyst opinions.

About Cytosorbents Corporation

Cytosorbents Corporation, headquartered in Princeton, New Jersey, is a healthcare company specializing in medical devices. It focuses on blood purification technologies, with its flagship product, CytoSorb, being used to treat cytokine storms and other critical conditions. The company also develops various other products aimed at reducing inflammatory mediators and managing blood purification in different medical scenarios. Founded in 1997, Cytosorbents operates both in the United States and internationally.

Bottom Line

Phillip Chan's recent purchase of Cytosorbents shares underscores his confidence in the company's future. Cytosorbents, known for its innovative blood purification technologies, continues to attract interest from institutional investors. However, potential investors should note that insider transactions are just one factor to consider and do not necessarily predict future stock performance.